GNH USA

Europe — EMA

Holmevis (Ibandronate Sodium Hydrate)

Holmevis ibandronate sodium hydrate IV solution for osteoporosis treatment – uses, mechanism, side effects, precautions, and drug interactions.

Ibandronate Sodium Hydrate

Request sourcing

1
Pack/s

What is Ibandronate Sodium Hydrate?

Holmevis is an intravenous solution containing the active ingredient ibandronate sodium hydrate. It is a prescription bisphosphonate used in the European market for the treatment of osteoporosis. The product is administered by healthcare professionals and is classified under ATC code M05BA07. Holmevis works by targeting bone metabolism to reduce the risk of fractures in patients with low bone density.

What is Ibandronate Sodium Hydrate used for?

Holmevis is indicated for the management of osteoporosis in specific patient groups. It is prescribed to help maintain bone strength and reduce fracture risk.

- Treatment of postmenopausal osteoporosis - Prevention of glucocorticoid‑induced osteoporosis - Long‑term management of established osteoporosis - Adjunct therapy for patients at high risk of vertebral fractures - Use in patients who cannot tolerate oral bisphosphonates

What are the side effects of Ibandronate Sodium Hydrate?

Adverse reactions to Holmevis can vary in frequency and severity.

Common: - Flu-like symptoms (fever, chills, myalgia) - Transient musculoskeletal pain - Nausea or mild gastrointestinal discomfort - Headache - Injection site reactions such as erythema or swelling

Serious: - Acute phase reaction with high fever - Severe renal impairment or acute kidney injury - Hypocalcemia leading to tetany or seizures - Atypical femoral fractures - Osteonecrosis of the jaw

What precautions apply to Ibandronate Sodium Hydrate?

Before initiating Holmevis, certain safety considerations should be reviewed.

- Assess renal function; avoid use in severe renal impairment (creatinine clearance <30 mL/min) - Correct calcium and vitamin D deficiencies prior to treatment - Monitor serum calcium levels during therapy - Use with caution in patients with a history of esophageal disorders - Evaluate for prior or current jaw pathology before administration - Discontinue if acute inflammatory reactions develop after infusion - Discuss pregnancy and lactation status; safety data are limited

What does Ibandronate Sodium Hydrate interact with?

Holmevis may interact with other medications, requiring attention to avoid reduced efficacy or increased toxicity.

Avoid: - Concomitant use of other bisphosphonates or potent nephrotoxic agents (e.g., aminoglycosides, NSAIDs) - High-dose calcium or magnesium supplements taken within 4 hours of infusion

Use with caution: - Loop diuretics that may affect calcium balance - Antacids containing aluminum or magnesium if administered close to the infusion time - Corticosteroids that increase osteoporosis risk - Vitamin D analogues that may alter calcium homeostasis - Drugs affecting renal function such as ACE inhibitors or ARBs

Frequently asked questions

What is the active ingredient in Holmevis and how is it administered?+
Holmevis contains ibandronate sodium hydrate as its active ingredient and is administered as an intravenous solution by a healthcare professional.
For which types of osteoporosis is Holmevis prescribed?+
Holmevis is prescribed for postmenopausal osteoporosis and for osteoporosis that results from long‑term glucocorticoid therapy.
How does ibandronate reduce bone loss?+
Ibandronate binds to bone mineral, is taken up by osteoclasts, and inhibits an enzyme in the mevalonate pathway, leading to osteoclast apoptosis and decreased bone resorption.
What are the most common side effects after an ibandronate IV infusion?+
Common side effects include flu‑like symptoms such as fever and chills, transient muscle or joint pain, mild nausea, headache, and local reactions at the injection site.
When should Holmevis be avoided because of kidney concerns?+
Holmevis should be avoided in patients with severe renal impairment, typically defined as a creatinine clearance below 30 mL/min, due to the risk of further kidney injury.
Do calcium supplements interfere with Holmevis treatment?+
Calcium or magnesium supplements taken within four hours of the infusion can reduce ibandronate absorption and should be avoided during that time window.
Is Holmevis safe to use during pregnancy?+
The safety of Holmevis in pregnancy has not been established; it should be used only if the potential benefit justifies the potential risk to the fetus.
What monitoring is recommended while a patient receives Holmevis?+
Renal function, serum calcium levels, and vitamin D status should be monitored before and during treatment with Holmevis.
Can Holmevis be given to patients who have had jaw surgery?+
Patients with a history of jaw surgery or dental disease should be evaluated carefully, as ibandronate is associated with a risk of osteonecrosis of the jaw.
How often is Holmevis typically administered?+
The dosing interval for ibandronate IV formulations varies; clinicians determine the schedule based on the specific product labeling and patient needs.
What should a patient do if they experience a severe acute phase reaction after infusion?+
Patients should contact their healthcare provider promptly; severe fever, chills, or other acute symptoms may require medical evaluation and possible discontinuation of therapy.
Are there any drug classes that should be avoided while on Holmevis?+
Concurrent use of other bisphosphonates, potent nephrotoxic drugs, and high‑dose calcium or magnesium supplements near the infusion time should be avoided.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Ibandronate Sodium Hydrate
Route
Intravenous Use
Manufacturer
Egis Pharmaceuticals Plc
Origin
EU

Related products

Etanorden

Etanorden

Ibandronate Sodium Hydrate

Gedeon Richter Plc.
EU
Holmevis

Holmevis

Ibandronate Sodium Hydrate

Egis Pharmaceuticals Plc
EU
Ibabon

Ibabon

Ibandronate Sodium Hydrate

Pharma Patent Kft.
EU
Ibandronic Acid Noridem

Ibandronic Acid Noridem

Ibandronate Sodium Hydrate

Noridem Enterprises Ltd
EU